Lecanemab reduced markers of amyloid in early Alzheimer’s disease
Dec 01, 2022
Moderately less decline was seen in cognition and function at 18 months with lecanemab versus placebo.
More than ADLs: Assisted living now is about treatment, Silverado CEO says
By
Lois A. Bowers
Sep 30, 2024
Assisted living is a “whole different world” compared with 28 years ago, Silverado CEO Loren Shook told those attending a session at the National Investment Center for Seniors Housing & Care’s...
New laws in California aim to reform service delivery to those living with dementia
By
Kimberly Bonvissuto
Sep 25, 2024
New laws in California govern the safety, care and accountability of providers who deliver services to people living with Alzheimer’s disease or another form of dementia.
House passes bill to strengthen public health infrastructure for dementia interventions
By
Kimberly Bonvissuto
Sep 24, 2024
A bipartisan bill funding Alzheimer’s interventions through public health departments throughout the country received unanimous support in the US House of Representatives last week and now heads to the...
Value-based care, tech, workforce issues among hot topics senior living experts dish on
By
Kimberly Bonvissuto
Sep 12, 2024
Innovation, technology, affordable assisted living, dementia and memory care, value-based care and workforce issues were among the hot topics senior living experts discussed during a McKnight’s Senior...
Business briefs, Sept. 9
By
Kathleen Steele Gaivin
Sep 09, 2024
Grace Management’s memory care training program recognized by Alzheimer’s Association curriculum review … Parasol Alliance chief Amber Bardon named Best & Brightest CEO … Help at Home expands Georgia...
Is Eli Lilly using ‘granfluencers’ to raise awareness of its Alzheimer’s med?
By
Marc Iskowitz
Sep 04, 2024
Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer’s drug marketing scene.
Multiple sclerosis linked to lower risk for Alzheimer’s disease pathology
By
Haymarket Media
Aug 30, 2024
A lower rate of amyloid-β plasma biomarker positivity was seen in multiple sclerosis patients compared with non-MS controls.
Risk for dementia similar with SGLT2 inhibitors, dulaglutide in T2DM
Aug 26, 2024
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.
Studies highlight increasing dementia deaths, contributing factors to diagnosis and cognitive decline
By
Kimberly Bonvissuto
Aug 16, 2024
More people are dying from dementia, and location and demographics are among the factors that may contribute to not only a dementia diagnosis, but also to how quickly someone will experience cognitive...